Update: Rheinmetall and Honeywell To Develop Combat-Ready Augmented Reality Technologies
Mon Sep 29 2024 – 10:42:40 UTC- Rheinmetall, a leading German arms maker, and U.S.-based Honeywell have signed a memorandum of understanding (MoU)…
Update: DHL Supply Chain Extends Partnership with Volkswagen Slovakia Through 2029
DHL Supply Chain has announced the extension of its logistics partnership with Volkswagen Slovakia. Effective until 2029, this long-term agreement continues a collaboration…
Update: Rheinmetall Secures Major Contract to Supply Skyranger 30 for Danish Mobile Air Defence
The agreement includes 16 Skyranger 30 turrets and additional equipment, valued in the low three-digit million euro range, the company said.
Pearson Expands Programs To Most Connections Academy Schools
Pearson plc expands college and early career programming to over half of Connections Academy schools in the country.
FDA Approves Keytruda With Chemotherapy For Advanced Mesothelioma
Merck in New Jersey announces FDA approval for KEYTRUDA® plus chemotherapy for mesothelioma treatment.
Daimler Truck Introduces New Digital Services For Vehicle Efficiency – IAA
Click this link for Daimler Truck's new digital services and service solutions for more efficient vehicle use.
Fasenra Approved in US For Treating GPA Wegner’s Disease in Adults
AstraZeneca's Fasenra approved in the US for treating eosinophilic granulomatosis with polyangiitis.
Indonesian Air Force Orders 4 Airbus H145 Helicopters
Indonesian Air Force orders four Airbus H145 helicopters for training modernization program and light search-and-rescue missions. The helicopters will be delivered to PT…
Update: Is the Pongamia Tree the New Diesel?
Rio Tinto begins biofuel crop farming trial in Australia to produce renewable diesel using Pongamia seed oil, aiming to reduce emissions and explore…
FDA Approves Novartis’s Kisqali For High-Risk Early Breast Cancer
FDA approves Novartis's Kisqali (ribociclib) with an aromatase inhibitor for HR+/HER2- stage II and III early breast cancer at high recurrence risk.